Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Οι συνταγές μου Αποθηκεύστε τις συνταγές σας και μοιραστείτε τις εύκολα και με ασφάλεια
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

TECHNESCAN PYP Kit for radiopharmaceutical preparation (2016)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

1. Name of the medicinal product

Technescan PYP, 20 mg kit for radiopharmaceutical preparation.

2. Qualitative and quantitative composition

Sodium pyrophosphate decahydrate 20 mg. The radionuclide is not part of the kit. <u>Excipient with known effect:</u> Stannous chloride dihydrate 4 mg corresponding to stannous 2.1 mg For a full list of ...

3. Pharmaceutical form

Kit for radiopharmaceutical preparation. White pellets or powder.

4.1. Therapeutic indications

This medicinal product is for diagnostic use only. After radiolabeling with sodium pertechnetate (<sup>99m</sup>Tc) solution, the solution obtained is indicated for A) In-vivo or in-vivo/in-vitro red blood ...

4.2. Posology and method of administration

Posology Adults A) Blood pool scintigraphy The average activity administered by single injection after in-vivo or in-vitro labelling is 890 MBq (740-925 MBq). B) Determination of blood volume The average ...

4.3. Contraindications

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to any of the components of the labelled radiopharmaceutical.

4.4. Special warnings and precautions for use

Potential for hypersensitivity or anaphylactic reactions If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous ...

4.5. Interaction with other medicinal products and other forms of interaction

Reduction in red blood cell labelling yield has been reported with heparin, tin overload, aluminium, prazosin, methyldopa, hydralazin, digitalis related compounds, quinidine, ß-adrenergic blockers (e.g. ...

4.6. Fertility, pregnancy and lactation

Women of childbearing potential When an administration of radioapharmaceutical to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant. Any woman who ...

4.7. Effects on ability to drive and use machines

Technescan PYP has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is 7.9 mSv when the maximal recommended activity of 925 MBq is ...

4.9. Overdose

In the event of administration of an overdose with Technescan PYP very little supportive treatment can be undertaken since its elimination is entirely dependent on the normal haemolytic process. Forced ...

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Diagnostic radiopharmaceuticals (<sup>99m</sup>Tc) Technetium compounds. ATC code: V09GA06 At doses used for diagnostic procedures, neither stannous pyrophosphate, sodium (<sup> ...

5.2. Pharmacokinetic properties

Distribution Intravenous injection of stannous salts induces a stannous loading of erythrocytes. Subsequent sodium (<sup>99m</sup>Tc) pertechnetate injection results in an accumulation and a retention ...

5.3. Preclinical safety data

There are no preclinical safety data specific to technetium labelled erythrocytes. The toxicity of pertechnetate ion and stannous salts has been studied and reported in the literature. Systemic toxical ...

6.1. List of excipients

Stannous chloride dihydrate Hydrochloric acid Sodium hydroxide

6.2. Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 12.

6.3. Shelf life

1 year. After radiolabelling: 4 hours. Store at 2°C-8°C after radiolabelling.

6.4. Special precautions for storage

Store at 2-8°C. For storage conditions after radiolabeling of the medicinal product see section 6.3. Storage of radiopharmaceuticals should be in accordance with national regulations for radioactive material. ...

6.5. Nature and contents of container

10 ml glass vial (Type 1 Ph. Eur) closed with a bromobutyl rubber stopper sealed with an aluminium crimp cap. TechneScan PYP is supplied as five vials in a carton.

6.6. Special precautions for disposal and other handling

General warnings Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject ...

7. Marketing authorization holder

Mallinckrodt Medical B.V., Westerduinweg 3, 1755 LE Petten, The Netherlands

8. Marketing authorization number(s)

PA 690/10/1

9. Date of first authorization / renewal of the authorization

Date of first authorisation: 29th June 2001 Date of last renewal: 29th June 2006

10. Date of revision of the text

January 2016
Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.